High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot

Simon P Keam; Heloise Halse; Thu Nguyen; Minyu Wang; Nicolas Van Kooten Losio; Catherine Mitchell; Franco Caramia; David J Byrne; Sue Haupt; Georgina Ryland; Phillip K Darcy; Shahneen Sandhu; Piers Blombery; Ygal Haupt; Scott G Williams; Paul J Neeson

Journal article

High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot

Simon P Keam, Heloise Halse, Thu Nguyen, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David J Byrne, Sue Haupt, Georgina Ryland, Phillip K Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott G Williams, Paul J Neeson

Journal for ImmunoTherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2020

DOI: 10.1136/jitc-2020-000792

Abstract

BACKGROUND: Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment and is commonly immune excluded with few infiltrative lymphocytes and low levels of immune activation. High-dose radiation has been demonstrated to stimulate the immune system in various human solid tumors. We hypothesized that localized radiation therapy, in the form of high dose-rate brachytherapy (HDRBT), would overcome immune suppression in PCa. METHODS: To investigate whether HDRBT altered prostate immune context, we analyzed preradiation versus postradiation human tissue from a cohort of 24 patients with localized PCa that received HDRBT as primary treatment (RadBank cohort). We performed Nanostring i..

View full abstract

University of Melbourne Researchers

Phillip Darcy Author The Sir Peter MacCallum Department of Oncology

Piers Blombery Author The Sir Peter MacCallum Department of Oncology

Susan Haupt Author Clinical Pathology

Georgie Ryland Author The Sir Peter MacCallum Department of Oncology

Scott Williams Author The Sir Peter MacCallum Department of Oncology

Related Projects (1)

Immunobiology And Immunotherapy Of Cancer

For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 year..

Grants

Funding Acknowledgements

This study was funded by the PeterMac Foundation, the Victorian Cancer Agency, a Prostate Cancer Foundation USA (Creativity award), Cancer Council Victoria (Grant-In-Aid), and an NHMRC Program Grant.